Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.

Breast cancer (Tokyo, Japan) - 1 Jul 2015

Xu Lingyun, Zhao Yansheng, Chen Zhiqiang, Wang Yujiao, Chen Lin, Wang Shui

Abstract excerpt

Given the greatly elevated risks of contralateral breast cancer (CBC) observed in breast cancer patients who carry mutation in BRCA1 or BRCA2, the present meta-analysis was addressed to determine whether adjuvant tamoxifen treatment for breast cancer is associated with reduced CBC risk for these patients. We searched the database of PubMed for eligible studies about the effectiveness of tamoxifen on CBC risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to BRCA2 gene

Share to Genetic Predisposition to Disease

Share to Mutation

Share to Selective Estrogen Receptor Modulators

Share to Tamoxifen

Source

Identifiers

PMID: 26022977
DOI: 10.1007/s12282-015-0619-6

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.PMID 26022977Read ↗

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysisSemantic proximity Read ↗

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.Semantic proximity Read ↗

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.Semantic proximity Read ↗

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.Semantic proximity Read ↗

Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.Semantic proximity Read ↗

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study.Semantic proximity Read ↗

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.Semantic proximity Read ↗

Bilateral breast cancers.Semantic proximity Read ↗

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.